JY
STLN

Jeff Yass’s Starling Oncology STLN Stock Holding History

Jeff Yass’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-92,869
Closed -$390K – 14537
2026
Q1 		$285K Sell
92,869
-202,281
-69% -$620K ﹤0.01% 10972
2025
Q4 		$1.05M Buy
+295,150
New +$1.09M ﹤0.01% 7069
2025
Q3 		– Sell
-113,676
Closed -$389K – 13895
2025
Q2 		$233K Buy
113,676
+91,288
+408% +$228K ﹤0.01% 10901
2025
Q1 		$25.5K Buy
+22,388
New +$17.3K ﹤0.01% 12056
2024
Q4 		– Sell
-34,411
Closed -$11.2K – 13230
2024
Q3 		$11.2K Buy
34,411
+3,229
+10% +$1.34K ﹤0.01% 11710
2024
Q2 		$14.3K Buy
+31,182
New +$26.6K ﹤0.01% 11725
2023
Q2 		– Sell
-44,019
Closed -$29.8K – 13144
2023
Q1 		$29.8K Buy
+44,019
New +$56.2K ﹤0.01% 11912
2022
Q4 		– Sell
-10,525
Closed -$49K – 13679
2022
Q3 		$49K Buy
+10,525
New +$61.9K ﹤0.01% 12222

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Jeff Yass's STLN Position: Q2 2026 in Review

Jeff Yass sold out of Starling Oncology (STLN) in Q2 2026, closing a stake of 92,869 shares — an estimated $390K sold.

Jeff Yass first reported a position in STLN in Q3 2022 and held it in 8 quarters. The position peaked at $1.05M in Q4 2025. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Jeff Yass reported no remaining Starling Oncology position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 92,869 Starling Oncology shares in Q2 2026, an estimated $390K.
  • Jeff Yass first reported a position in Starling Oncology in Q3 2022 and held it in 8 quarters.
  • Jeff Yass's Starling Oncology position peaked at $1.05M in Q4 2025.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.